Kolon Life Science Statistics

Total Valuation

Kolon Life Science has a market cap or net worth of KRW 282.01 billion. The enterprise value is 381.25 billion.

Market Cap	282.01B
Enterprise Value	381.25B

Important Dates

The next estimated earnings date is Thursday, March 13, 2025.

Earnings Date	Mar 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Kolon Life Science has 12.42 million shares outstanding. The number of shares has increased by 2.43% in one year.

Current Share Class	n/a
Shares Outstanding	12.42M
Shares Change (YoY)	+2.43%
Shares Change (QoQ)	+7.41%
Owned by Insiders (%)	18.06%
Owned by Institutions (%)	0.20%
Float	6.94M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.79
PB Ratio	2.49
P/TBV Ratio	2.51
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.25
EV / Sales	2.58
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-12.85

Financial Position

The company has a current ratio of 0.51, with a Debt / Equity ratio of 1.00.

Current Ratio	0.51
Quick Ratio	0.22
Debt / Equity	1.00
Debt / EBITDA	n/a
Debt / FCF	-3.79
Interest Coverage	-3.76

Financial Efficiency

Return on equity (ROE) is -68.04% and return on invested capital (ROIC) is -7.13%.

Return on Equity (ROE)	-68.04%
Return on Assets (ROA)	-5.14%
Return on Capital (ROIC)	-7.13%
Revenue Per Employee	352.33M
Profits Per Employee	-213.73M
Employee Count	420
Asset Turnover	0.45
Inventory Turnover	2.32

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -11.76% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-11.76%
50-Day Moving Average	19,396.40
200-Day Moving Average	21,072.20
Relative Strength Index (RSI)	61.02
Average Volume (20 Days)	82,598

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kolon Life Science had revenue of KRW 147.98 billion and -89.77 billion in losses. Loss per share was -7,681.82.

Revenue	147.98B
Gross Profit	9.97B
Operating Income	-27.06B
Pretax Income	-89.74B
Net Income	-89.77B
EBITDA	-18.67B
EBIT	-27.06B
Loss Per Share	-7,681.82

Full Income Statement

Balance Sheet

The company has 13.26 billion in cash and 112.50 billion in debt, giving a net cash position of -99.24 billion or -7,988.23 per share.

Cash & Cash Equivalents	13.26B
Total Debt	112.50B
Net Cash	-99.24B
Net Cash Per Share	-7,988.23
Equity (Book Value)	113.05B
Book Value Per Share	9,099.77
Working Capital	-91.86B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -21.35 billion and capital expenditures -8.31 billion, giving a free cash flow of -29.66 billion.

Operating Cash Flow	-21.35B
Capital Expenditures	-8.31B
Free Cash Flow	-29.66B
FCF Per Share	-2,387.71

Full Cash Flow Statement

Margins

Gross margin is 6.74%, with operating and profit margins of -18.29% and -60.66%.

Gross Margin	6.74%
Operating Margin	-18.29%
Pretax Margin	-60.65%
Profit Margin	-60.66%
EBITDA Margin	-12.62%
EBIT Margin	-18.29%
FCF Margin	n/a

Dividends & Yields

Kolon Life Science does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.43%
Shareholder Yield	-2.43%
Earnings Yield	-33.84%
FCF Yield	-10.52%

Stock Splits

The last stock split was on December 27, 2017. It was a forward split with a ratio of 1.5.

Last Split Date	Dec 27, 2017
Split Type	Forward
Split Ratio	1.5

Scores

Kolon Life Science has an Altman Z-Score of -0.29. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.29
Piotroski F-Score	n/a